Precigen (PGEN)

• Market cap: $226M
• 1 day: -4.24%
• 5 days: -15.30%
• 1 month: -6.37%
• 3 months: -19.62%
• 6 months: -55.95%
• Year to date: -45.33%
• 1 year: -36.82%
• 5 years: -85.62%
• 10 years: -96.84%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Employees: 202

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

484% more call options, than puts

Call options by funds: $403K | Put options by funds: $69K

1.73% more ownership

Funds ownership: 24.46% [Q2] → 26.19% (+1.73%) [Q3]

9% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 33

2% less funds holding

Funds holding: 130 [Q2] → 127 (-3) [Q3]

16% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 19

26% less capital invested

Capital invested by funds: $97.5M [Q2] → $71.7M (-$25.8M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 419% upside
• Avg. target: $4 419% upside
• High target: $4 419% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 38% 1-year accuracy 39 / 103 met price target

419% upside $4

Buy Reiterated

15 Nov 2024